Effect Of Sarpagandha Vati and Haritaki churna in hypertensio
Phase 4
- Conditions
- Health Condition 1: I10- Essential (primary) hypertensionHealth Condition 2: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2024/05/067985
- Lead Sponsor
- Ch Brahm Prakash Ayurved Charak Sansthan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient of either sex with age between 18-50 years.
Newly diagnosed stage1 primary hypertensive patients( not on medication)
Exclusion Criteria
Primary hypertension other than stage1 eg. stage2, Benign hypertension, malignant hypertension, isolated hypertension.
Secondary hypertension.
Stage1, primary hypertension with co morbidities.
Stage1 hypertensive patient on regular medication.
Pregnant woman and lactating mother.
Gestational hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by Sarpagandha Vati and Haritaki churna in essential hypertension management?
How does the Sarpagandha-Haritaki combination compare to standard antihypertensive drug classes like ACE inhibitors in phase IV trials?
Which biomarkers correlate with improved blood pressure outcomes in patients receiving Sarpagandha Vati and Haritaki churna therapy?
What are the potential adverse event profiles and mitigation strategies for Sarpagandha Vati and Haritaki churna in hypertension treatment?
Are there other Ayurvedic formulations with similar antihypertensive efficacy to Sarpagandha Vati and Haritaki churna combination?